Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
Metformin, a synthetic derivative of guanidine, is commonly used as an oral antidiabetic agent and is considered a multi-vector application agent in the treatment of other inflammatory diseases. Recent studies have confirmed the beneficial effect of metformin on immune cells, with special emphasis o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/5957 |
| _version_ | 1797557056166690816 |
|---|---|
| author | Angela Dziedzic Joanna Saluk-Bijak Elzbieta Miller Michal Bijak |
| author_facet | Angela Dziedzic Joanna Saluk-Bijak Elzbieta Miller Michal Bijak |
| author_sort | Angela Dziedzic |
| collection | DOAJ |
| description | Metformin, a synthetic derivative of guanidine, is commonly used as an oral antidiabetic agent and is considered a multi-vector application agent in the treatment of other inflammatory diseases. Recent studies have confirmed the beneficial effect of metformin on immune cells, with special emphasis on immunological mechanisms. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by various clinical courses. Although the pathophysiology of MS remains unknown, it is most likely a combination of disturbances of the immune system and biochemical pathways with a disruption of blood–brain barrier (BBB), and it is strictly related to injury of intracerebral blood vessels. Metformin has properties which are greatly desirable for MS therapy, including antioxidant, anti-inflammatory or antiplatelet functions. The latest reports relating to the cardiovascular disease confirm an increased risk of ischemic events in MS patients, which are directly associated with a coagulation cascade and an elevated pro-thrombotic platelet function. Hence, this review examines the potential favourable effects of metformin in the course of MS, its role in preventing inflammation and endothelial dysfunction, as well as its potential antiplatelet role. |
| first_indexed | 2024-03-10T17:11:47Z |
| format | Article |
| id | doaj.art-209b1d4c48134735adc0105a03fd33c2 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T17:11:47Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-209b1d4c48134735adc0105a03fd33c22023-11-20T10:37:55ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-012117595710.3390/ijms21175957Metformin as a Potential Agent in the Treatment of Multiple SclerosisAngela Dziedzic0Joanna Saluk-Bijak1Elzbieta Miller2Michal Bijak3Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, PolandDepartment of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, PolandDepartment of Neurological Rehabilitation, Medical University of Lodz, Milionowa 14, 93-113 Lodz, PolandBiohazard Prevention Centre, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, PolandMetformin, a synthetic derivative of guanidine, is commonly used as an oral antidiabetic agent and is considered a multi-vector application agent in the treatment of other inflammatory diseases. Recent studies have confirmed the beneficial effect of metformin on immune cells, with special emphasis on immunological mechanisms. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) characterized by various clinical courses. Although the pathophysiology of MS remains unknown, it is most likely a combination of disturbances of the immune system and biochemical pathways with a disruption of blood–brain barrier (BBB), and it is strictly related to injury of intracerebral blood vessels. Metformin has properties which are greatly desirable for MS therapy, including antioxidant, anti-inflammatory or antiplatelet functions. The latest reports relating to the cardiovascular disease confirm an increased risk of ischemic events in MS patients, which are directly associated with a coagulation cascade and an elevated pro-thrombotic platelet function. Hence, this review examines the potential favourable effects of metformin in the course of MS, its role in preventing inflammation and endothelial dysfunction, as well as its potential antiplatelet role.https://www.mdpi.com/1422-0067/21/17/5957metforminneurodegenerationmultiple sclerosis |
| spellingShingle | Angela Dziedzic Joanna Saluk-Bijak Elzbieta Miller Michal Bijak Metformin as a Potential Agent in the Treatment of Multiple Sclerosis International Journal of Molecular Sciences metformin neurodegeneration multiple sclerosis |
| title | Metformin as a Potential Agent in the Treatment of Multiple Sclerosis |
| title_full | Metformin as a Potential Agent in the Treatment of Multiple Sclerosis |
| title_fullStr | Metformin as a Potential Agent in the Treatment of Multiple Sclerosis |
| title_full_unstemmed | Metformin as a Potential Agent in the Treatment of Multiple Sclerosis |
| title_short | Metformin as a Potential Agent in the Treatment of Multiple Sclerosis |
| title_sort | metformin as a potential agent in the treatment of multiple sclerosis |
| topic | metformin neurodegeneration multiple sclerosis |
| url | https://www.mdpi.com/1422-0067/21/17/5957 |
| work_keys_str_mv | AT angeladziedzic metforminasapotentialagentinthetreatmentofmultiplesclerosis AT joannasalukbijak metforminasapotentialagentinthetreatmentofmultiplesclerosis AT elzbietamiller metforminasapotentialagentinthetreatmentofmultiplesclerosis AT michalbijak metforminasapotentialagentinthetreatmentofmultiplesclerosis |